Results 11 to 20 of about 4,310 (188)
Medication-Related Osteonecrosis: Why the Jawbone?
Dentistry Journal, 2023 Medication-related osteonecrosis of the jaw (MRONJ) has emerged as a complication of anti-resorptive medications. Despite its low incidence rate, this problem has gained attention in recent years due to its devastating consequences and lack of preventive
Sydney Kuehn +2 more
doaj +1 more source
Applied Sciences, 2022 Osteonecrosis of the jaw represents interference by external and internal factors in the natural bone remodeling system. Numerous bone remodeling agents (BMAs), such as bisphosphonates, denosumab, and tyrosine kinase inhibitors, can lead to medication ...
Mihai Vlad Golu +6 more
doaj +1 more source
Medication-related Osteonecrosis of the Jaw: A Review [PDF]
Cureus, 2020 Medication-related osteonecrosis of the jaw (MRONJ) is a rare, severe debilitating condition from unknown causes. It is characterized by nonhealing exposed bone in a patient with a history of antiresorptive or antiangiogenic agents in the absence of radiation exposure to the head and neck region. The first case of MRONJ was reported in the early 2000s.
AlDhalaan, Nouf A +2 more
openaire +2 more sources
BMC Oral Health, 2021 Background Accurate documentation of a patient’s prior medication use and awareness of side effects associated with anti-osteoporotic agents can assist dentists to prevent medication-related osteonecrosis of the jaw. I aimed to determine the awareness of
A. Lum Han
doaj +1 more source
Medication-Related Osteonecrosis of the Jaws
JNCI Monographs, 2019 AbstractMedication-related osteonecrosis of the jaw is an oral complication in cancer patients being treated with either antiresorptive or antiangiogenic drugs. The first reports of MRONJ were published in 2003. Hundreds of manuscripts have been published in the medical and dental literature describing the complication, clinical and radiographic signs ...
Cesar A, Migliorati +2 more
openaire +5 more sources
Dentistry Journal, 2021 Medication-related osteonecrosis of the jaw (MRONJ) frequently affects patients after treatments with bisphosphonates or denosumab, especially with high doses in patients with bone osteoporosis, neoplastic metastases, or possibly anti-angiogenic ...
Antonio Cortese +3 more
doaj +1 more source
The Prevention of Medication-related Osteonecrosis of the Jaw [PDF]
Deutsches Ärzteblatt international, 2017 Medication-related osteonecrosis of the jaw (MRONJ) is a preventable complication of antiresorptive treatment. It arises in 1-20% of patients with bone metastases of solid tumors and hematologic malignancies and in 0.1-2% of patients being treated for osteoporosis with bisphosphonates. Depending on the underlying disease and medication dosage, the risk
Poxleitner, Philipp +3 more
openaire +3 more sources
Clinical Case Reports, 2023 Key Clinical Message Chronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a ...
Kazuhiko Iwasaki, Akihito Okazaki
doaj +1 more source
Fatal infectious encephalitis as a complication of medication-related osteonecrosis of the jaw
Oral and Maxillofacial Surgery Cases, 2020 We present a unique case of bacterial encephalitis in a 79-year-old female due to progression of medication-related osteonecrosis of the jaw. The occurrence of this life-threatening neurologic condition following the expansion of medication-related ...
Hye-Won Kim +3 more
doaj +1 more source
The Use of Photodynamic Therapy on Medication-Related Osteonecrosis of the Jaws: Animal Study
Balkan Journal of Dental Medicine, 2021 Background/Aim: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was first introduced in 2003 and its scope was expanded by the name medication-related osteonecrosis of the jaw (MRONJ), since 2014.
Karapinar Gökay +3 more
doaj +1 more source